RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Testing targeted magnetic brain stimulation for movement symptoms

Researchers test the safety and effects of carefully targeted magnetic stimulation applied outside the head for movement symptoms in Parkinson’s.

Testing a treatment or activity · Study reference: NCT06383247

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2024-12-06
Main measurements finished (planned)
2026-12-31
Study finished (planned)
2028-12-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

The efficacy and safety of precision repetitive transcranial magnetic stimulation in alleviating motor symptoms in Parkinson's disease (PRESS-PD): a randomized, double-blind, multicenter, placebo-controlled trial.
Listed by the registry as research derived from the study · 2026

Who can join?

Age 40 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: 1. Age ≥ 40 years old; 2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\[1\]; 3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period; 4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4; 5. MMSE ≥22,able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy. Exclusion Criteria: 1. Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above); 2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.); 3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment; 4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc. 5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures; 6. Diagnosed with a neuropsychiatric disorder other than PD 7. Have a history of drug abuse or drug use; 8. Participants in any clinical trial within the previous 6 month; 9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months; 10. Other conditions deemed unsuitable for inclusion by the investigator.
Full study name & original research details

Official study title

A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)

Short title used by the registry

The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease

Original description

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.

Further description from the registry

This is a multi-center, double-blind, randomized controlled study that will be implemented in multiple hospital centers in China. In this study, the supplementary motor area (SMA) of the dominant hemisphere was selected as the stimulation target, and continuous theta burst stimulation (cTBS) sequence contact stimulation was used for a course of continuous stimulation for 7 days to observe the changes in clinical symptoms before and after the intervention.

Conditions reported: Parkinson Disease; Transcranial Magenetic Stimualtion; Supplementary Motor Area

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
transcranial magnetic stimulation
Phases
NA
Sponsor
Anhui Medical University
Start date reported by registry
2024-12-06 (actual)

Registry updated: 2025-06-17 · Status last verified by the registry submitter: 2025-06

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Panpan Hu, M.D. · +8613515602285 · hpppanda9@126.com

Kai Wang, Ph.D. · +8655162923704 · wangkai1964@126.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Cognitive Neuropsychology Lab Anhui Medical University

Hefei, Anhui, China

Recruiting

panpan hu, M.D. · +8655162923704 · hpppanda9@126.com

Facility not reported

China

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.